The costs and consequences of multiple sclerosis relapses: a managed care perspective.
J Neurol Sci
; 256 Suppl 1: S39-44, 2007 May 15.
Article
em En
| MEDLINE
| ID: mdl-17362995
ABSTRACT
One of the more common "rare diseases," multiple sclerosis (MS) offers a prototype to managed care for a unique and cost-effective model to better manage the outcomes of this dreaded disease. Using a specialty pharmacy model, the application of traditional disease management processes, including monthly contact, selected clinical assessments combined with targeted interventions, and data collection and analysis, hold the promise to significantly lower the relapse rate and disability progression for patients with MS. At the same time, savings in both direct and indirect costs should occur.
Buscar no Google
Temas:
ECOS
/
Aspectos_gerais
/
Estado_mercado_regulacao
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Programas de Assistência Gerenciada
/
Custos de Cuidados de Saúde
/
Gerenciamento Clínico
/
Esclerose Múltipla Recidivante-Remitente
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
J Neurol Sci
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos